A roundup of manufacturing news from Chiesi and Entos Pharmaceuticals. Highlights below.

* Chiesi Investing $464 M for Inhaler Mfg Facility
* Entos Plans New R&D and Biomanufacturing Facility for Nucleic-Acid Based Drug Delivery

---

Chiesi Investing $464 M for Inhaler Mfg Facility
Chiesi Group, a Parma, Italy-based bio/pharmaceutical company, has announced a EUR 430-million ($464-million) investment for the construction of a new manufacturing facility in Nerviano, Milan, Italy, primarily dedicated to carbon-minimal inhalers. Dry-powder inhalers and sterile biological products will also be developed in Nerviano.

The investment will be spread between 2025 and 2030 and will fund the redevelopment of a 124,000-square-meter industrial area, transforming it into a a global center of excellence. This initiative is part of the Chiesi’s global industrial strategy, which includes ongoing investments in its facilities in Parma, Italy, and Blois, France, and operations in Santana de Parnaíba, Brazil, to meet the growing needs of people living with respiratory conditions. The objective is to support the company’s growth and its goal of achieving net-zero emissions by 2035.

Source: Chiesi Group

---

Entos Plans New R&D and Biomanufacturing Facility for Nucleic-Acid Based Drug Delivery
Entos Pharmaceuticals, a clinical-stage genetic medicines company, has announced $77.5 million in funding from the governments of Canada ($62 million) and Alberta ($15.5 billion) to support Entos’ $198.5-million project to create a R&D center and GMP biomanufacturing facility in Edmonton, Alberta, Canada, for the company’s proprietary Fusogenix PLV drug-delivery system, which enables the delivery of nucleic acids to target cells through direct fusion.

The project builds on a partnership with Eli Lilly & Company to research, develop, and commercialize nucleic-acid products targeting the central and peripheral nervous system. The company is a spin-off from the University of Alberta (since 2016) and is headquartered in Edmonton, Canada, with its wholly owned US and UK subsidiaries based in San Diego, California, and London, respectively.

Source: Entos Pharmaceuticals